Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Next Previous
X
Search
Trial Profile

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apalutamide (Primary) ; Degarelix; Docetaxel; Goserelin; Leuprorelin; Triptorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STARTAR

    • Most Recent Events

    • 06 Jun 2023 Results of Primary analysis assessing safety and efficacy of of androgen receptor (AR) inhibition with androgen deprivation therapy and apalutamide with radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 09 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 13 Feb 2021 interim analysis of (n=39) with a data cutoff in 9/2020 evaluated secondary endpoints of 1-year PSA recurrence, testosterone recovery, and safety of this treatment sequence presented at the 2021 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top